Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Genmab A/S
< Previous
1
2
3
Next >
Genmab Announces Changes to its Executive Committee
Today 8:00 EDT
From
Genmab A/S
Via
GlobeNewswire
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
June 02, 2025
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2025
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
May 14, 2025
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab Announces Financial Results for the First Quarter of 2024
May 08, 2025
From
Genmab A/S
Via
GlobeNewswire
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
May 01, 2025
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
May 01, 2025
From
Genmab A/S
Via
GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
April 15, 2025
From
Genmab A/S
Via
GlobeNewswire
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
March 31, 2025
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
March 27, 2025
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
March 21, 2025
From
Genmab A/S
Via
GlobeNewswire
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
March 10, 2025
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
March 10, 2025
From
Genmab A/S
Via
GlobeNewswire
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
February 20, 2025
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab Publishes 2024 Annual Report
February 12, 2025
From
Genmab A/S
Via
GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
January 22, 2025
From
Genmab A/S
Via
GlobeNewswire
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
December 09, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
December 08, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
December 07, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab Announces Financial Results for the First Nine Months of 2024
November 06, 2024
From
Genmab A/S
Via
GlobeNewswire
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
November 05, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
October 15, 2024
From
Genmab A/S
Via
GlobeNewswire
Major Shareholder Announcement
October 04, 2024
From
Genmab A/S
Via
GlobeNewswire
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
September 15, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
August 19, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
August 19, 2024
From
Genmab A/S
Via
GlobeNewswire
Genmab Announces Changes to its Executive Committee
August 16, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab Announces Financial Results for the First Half of 2024
August 08, 2024
From
Genmab A/S
Via
GlobeNewswire
Genmab Updates 2024 Financial Guidance
August 08, 2024
From
Genmab A/S
Via
GlobeNewswire
Genmab Takes Full Control of Acasunlimab Development Program
August 05, 2024
From
Genmab A/S
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.